Clinical Trials Logo

Neoplastic Syndrome clinical trials

View clinical trials related to Neoplastic Syndrome.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT01553448 Completed - Neuroblastoma Clinical Trials

Studying Gene Expression in Samples From Younger Patients With Neuroblastoma

Start date: March 2012
Phase: N/A
Study type: Observational

RATIONALE: Studying samples of blood and tumor tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer. It may also help doctors find better ways to treat cancer. PURPOSE: This research trial studies gene expression in samples from younger patients with neuroblastoma.

NCT ID: NCT00489086 Completed - Neoplastic Syndrome Clinical Trials

Topical Tazarotene in Treating Patients With Basal Cell Skin Cancer and Basal Cell Nevus Syndrome on the Face

Start date: July 2004
Phase: Phase 2
Study type: Interventional

RATIONALE: Drugs used in chemotherapy, such as tazarotene, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. PURPOSE: This phase II trial is studying topical tazarotene to see how well it works in treating patients with basal cell skin cancer and basal cell nevus syndrome on the face.

NCT ID: NCT00433485 Completed - Clinical trials for Non-melanomatous Skin Cancer

Topical Sirolimus in Patients With Basal Cell Nevus Syndrome and in Healthy Participants

Start date: n/a
Phase: Phase 1
Study type: Interventional

RATIONALE: Studying samples of blood and tissue from patients with basal cell nevus syndrome and from healthy participants in the laboratory may help doctors learn more about changes that may occur in DNA and identify biomarkers related to basal cell nevus syndrome. Chemoprevention is the use of certain drugs to keep cancer from forming, growing, or coming back. The use of sirolimus may keep basal cell skin cancer from forming in patients with basal cell nevus syndrome. PURPOSE: This phase I trial is studying topical sirolimus in patients with basal cell nevus syndrome and in healthy participants.

NCT ID: NCT00427349 Completed - Clinical trials for Gastrointestinal Carcinoid Tumor

AMG 706 and Octreotide in Treating Patients With Low-Grade Neuroendocrine Tumors

Start date: November 7, 2008
Phase: Phase 2
Study type: Interventional

RATIONALE: AMG 706 and octreotide may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. PURPOSE: This phase II trial is studying how well AMG 706 and octreotide work in treating patients with low-grade neuroendocrine tumors.

NCT ID: NCT00416767 Completed - Clinical trials for Gastrointestinal Carcinoid Tumor

Combination Chemotherapy as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Neuroendocrine Tumors of the Duodenum or Pancreas That Cannot Be Removed By Surgery

Start date: May 2004
Phase: Phase 2
Study type: Interventional

RATIONALE: Drugs used in chemotherapy, such as fluorouracil, leucovorin, and irinotecan, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more tumor cells. PURPOSE: This phase II trial is studying how well combination chemotherapy works as first-line therapy in treating patients with locally advanced or metastatic neuroendocrine tumors of the duodenum or pancreas that cannot be removed by surgery.

NCT ID: NCT00027638 Completed - Lung Cancer Clinical Trials

Thalidomide in Treating Patients With Metastatic Neuroendocrine Tumors

Start date: March 2001
Phase: Phase 2
Study type: Interventional

RATIONALE: Thalidomide may stop the growth of neuroendocrine tumors by stopping blood flow to the tumor. PURPOSE: Phase II trial to study the effectiveness of thalidomide in treating patients who have metastatic neuroendocrine tumors.

NCT ID: NCT00006368 Completed - Breast Cancer Clinical Trials

Yttrium Y 90 SMT 487 in Treating Patients With Refractory or Recurrent Cancer

Start date: January 1998
Phase: Phase 1
Study type: Interventional

RATIONALE: Radiolabeled drugs such as yttrium Y 90 SMT 487 can locate tumor cells and deliver tumor-killing substances to them without harming normal cells. PURPOSE: Phase I trial to study the effectiveness of yttrium Y 90 SMT 487 in treating patients who have refractory or recurrent cancer.